利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.035 秒)

    Novel CD40 variants
    4.
    发明申请
    Novel CD40 variants 审中-公开
    新型CD40变体

    公开(公告)号：US20060287229A1

    公开(公告)日：2006-12-21

    申请号：US11172493

    申请日：2005-06-30

    申请人： Dani Eshel ,  Galit Rotman ,  Kinneret Savitsky ,  Amir Toporik ,  Rami Khosravi ,  Aviva Chen ,  Yona Bismuth

    发明人： Dani Eshel ,  Galit Rotman ,  Kinneret Savitsky ,  Amir Toporik ,  Rami Khosravi ,  Aviva Chen ,  Yona Bismuth

    IPC分类号： A61K38/17

    CPC分类号： A61K38/177

    摘要： The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of selectively binding to the amino acid of CD40 skipping 5 and pharmaceutical composition comprising the above antibody and methods for detecting the presence of exon 5 skipping expression in a sample are also within the scope of the invention.

    摘要翻译： 本发明涉及跳过5个核酸序列和通过CD40的选择性剪接获得的氨基酸序列，包含所述序列的药物组合物和治疗疾病的方法的CD40，其中有益的治疗效果通过上调CD40-R- CD40-L相互作用。 能够选择性地结合CD40跳跃5的氨基酸的抗体和包含上述抗体的药物组合物和用于检测样品中外显子5跳跃表达的存在的方法也在本发明的范围内。

    CD40 splice variants, compositions for making and methods of using the same
    6.
    发明申请
    CD40 splice variants, compositions for making and methods of using the same 审中-公开
    CD40拼接变体，用于制备的组合物及其使用方法

    公开(公告)号：US20050272050A1

    公开(公告)日：2005-12-08

    申请号：US10924074

    申请日：2004-08-23

    申请人： Liat Mintz ,  Jeanne Bernstein ,  Dani Eshel ,  Amir Toporik ,  Aviva Chen

    发明人： Liat Mintz ,  Jeanne Bernstein ,  Dani Eshel ,  Amir Toporik ,  Aviva Chen

    IPC分类号： A61K48/00 ,  C07H21/04 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28 ,  C12N15/12 ,  C12Q1/68

    CPC分类号： C07K16/2878 ,  A61K48/00 ,  C07K14/70578 ,  C12N2799/026

    摘要： Provided are substantially pure CD40 splice variants that include altered internal sequences and unique tail sequences relative to previously described CD40 protein sequences. Also provided are fragments of the CD40 splice variants comprising at least 10 amino acids including at least 4 amino acids of the unique tail sequence; the unique tail sequences, and homologues thereof having at least 10 amino acids and 90% identity and antibodies which bind to an epitope on such proteins are disclosed. Pharmaceutical compositions comprising the protein, antibodies, isolated nucleic acid molecule that encode such proteins and pharmaceutical composition comprising such nucleic acid molecules are also disclosed. The present invention additionally relates to recombinant expression vectors that include the nucleic acid molecules and host cells which comprise such recombinant expression vectors are disclosed. In vitro methods of detecting in a sample the presence and/or quantity of such proteins or transcript which encodes such proteins are disclosed as are kits and reagents for performing the methods. Methods of modulating CD40-CD154 interactions in an individual are disclosed.

    摘要翻译： 提供基本上纯的CD40剪接变体，其包括相对于先前描述的CD40蛋白序列的改变的内部序列和唯一的尾部序列。 还提供了CD40剪接变体的片段，其包含至少10个氨基酸，包括唯一尾部序列的至少4个氨基酸; 公开了具有至少10个氨基酸和90％同一性的独特的尾部序列及其同源物，并且与这些蛋白质上的表位结合的抗体。 还公开了包含蛋白质，抗体，编码这种蛋白质的分离的核酸分子和包含此类核酸分子的药物组合物的药物组合物。 本发明还涉及包含核酸分子和包含这种重组表达载体的宿主细胞的重组表达载体。 在样本中检测体外的方法，公开了编码这种蛋白质的这些蛋白质或转录物的存在和/或数量，作为用于进行该方法的试剂盒和试剂。 公开了调节个体中CD40-CD154相互作用的方法。